北京康辰药业股份有限公司 关于以集中竞价交易方式首次回购公司股份暨股份回 购进展公告 证券代码：603590 证券简称：康辰药业 公告编号：临 2025-065 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关法律法规规定，现将公司首次回购股份情况公告如下： 2025 年 10 月 20 日，公司通过集中竞价交易方式首次回购股份 377,400 股， 已回购股份占公司总股本的比例为 0.24%，购买的最高价为 51.40 元/股，最低价 为 49.69 元/股，已支付的总金额为 19,150,565 元。本次股份回购符合法律法规的 有关规定和公司股份回购方案的要求。 三、其他事项 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/10/16，由董事会提议 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 15 10 ...

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-064 北京康辰药业股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 控股股东及其一致行动人保证向本公司提供的信息真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 | 一致行动人名称 | | 投资者身份 | 统一社会信用代码 | | | --- | --- | --- | --- | --- | | | □ | 控股股东/实控人 | | | | 北京沐仁投资管理有 | ☑ | 控股股东/实控人的一致 | ☑ 911101087754801507 | _ | | 限公司 | 行动人 | | □ 不适用 | | | | □ | 其他直接持股股东 | | | | | □ | 控股股东/实控人 | | | | 北京普华基业投资顾 问中心（有限合伙） | ☑ | 控股股东/实控人的一致 | 91110108061339040X_ ☑ | | | | 行动人 | | □ 不适用 | | | | □ | 其他直接持股股东 | | | 二、 权益变动触及 1%刻度的基本情况 | | ☑控股股东/实际控制人及其一致行动人 □其他 ...

Core Insights - Kangchen Pharmaceutical's stock rose by 4.00% on October 20, closing at 51.19 yuan, with a total of 16 block trades amounting to 4,473.87 million yuan [1][5] Trading Activity - The first block trade occurred at a price of 44.30 yuan for 112,000 shares, totaling 4.96 million yuan, with a discount rate of -13.46% [1] - Subsequent trades consistently occurred at the same price of 44.30 yuan, with varying volumes and total amounts, all reflecting a discount rate of -13.46% [2][3][4][5] - Over the past three months, the stock has seen a total of 25 block trades, with a cumulative transaction amount of 120 million yuan [5] - In the last five trading days, the stock has increased by 3.08%, while the net outflow of main funds amounted to 3.106 million yuan [5]

Core Viewpoint - On October 20, Kangchen Pharmaceutical executed a block trade of 1,009,900 shares, amounting to 44.7387 million yuan, which accounted for 12.69% of the total trading volume for the day. The transaction price was 44.3 yuan, representing a discount of 13.46% compared to the market closing price of 51.19 yuan [1]. Summary by Category - **Transaction Details** - The block trade involved 1,009,900 shares at a price of 44.3 yuan per share [1]. - The total transaction value was 44.7387 million yuan [1]. - This trade constituted 12.69% of the total trading volume on that day [1]. - The transaction price reflected a discount of 13.46% from the market closing price of 51.19 yuan [1]. - **Trading Date and Security Information** - The trade occurred on October 20, 2025, for Kangchen Pharmaceutical, with the stock code 603590 [2]. - Multiple transactions were recorded on the same date, all at the same price of 44.3 yuan [2].

Group 1 - The core point of the article highlights the recent performance of Kangchen Pharmaceutical, which saw a 5.02% increase in stock price, reaching 51.69 yuan per share, with a total market capitalization of 8.237 billion yuan [1] - Kangchen Pharmaceutical, established on September 3, 2003, and listed on August 27, 2018, focuses on innovative drug research and development, with its main revenue sources being Suling (70.77%) and Salmon Calcitonin (29.15%) [1] - The trading volume for Kangchen Pharmaceutical was 147 million yuan, with a turnover rate of 1.84% [1] Group 2 - According to data, CITIC Prudential Fund holds a significant position in Kangchen Pharmaceutical, with its CITIC Prudential Zhi Rui Mixed A Fund (003432) owning 228,000 shares, accounting for 3.05% of the fund's net value [2] - The fund has generated a floating profit of approximately 563,200 yuan today [2] - The CITIC Prudential Zhi Rui Mixed A Fund was established on October 21, 2016, with a current scale of 129 million yuan and has achieved a year-to-date return of 9.75% [2] Group 3 - The fund manager team for CITIC Prudential Zhi Rui Mixed A includes Wang Rui, Liu Hongliang, and Zhu Huiling, with Wang Rui having a tenure of 10 years and 177 days, achieving a best fund return of 253.09% during his tenure [3] - Liu Hongliang has a tenure of 1 year and 97 days, with a best fund return of 11.17% [3] - Zhu Huiling has a tenure of 202 days, with a best fund return of 10.12% [3]

格隆汇10月17日丨康辰药业(603590.SH)公布，股东刘建华先生于2025年10月17日通过集中竞价和大宗 交易的方式，合计减持公司股份102.15万股。本次权益变动后，股东刘建华先生及其一致行动人合计持 有公司股份数量由7536.34万股减少至7434.19万股，合计持有公司股份比例由47.29%减少至46.65%，权 益变动触及1%刻度。 ...

一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | ☑控股股东/实际控制人及其一致行动人 □其他 | | --- | --- | | | 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | 2.信息披露义务人信息 证券代码：603590 证券简称：康辰药业 公告编号：临 2025-063 北京康辰药业股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的 提示性公告 控股股东及其一致行动人保证向本公司提供的信息真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 北京康辰药业股份有限公司（以下简称"公司"）股东刘建华先生于 2025 年 10 月 17 日通过集中竞价和大宗交易的方式，合计减持公司股份 1,021,500 股。 本次权益变动后，股东刘建华先生及其一致行动人合计持有公司股份数量由 75,363,360 股减少至 74,341,860 股，合计 ...

Core Points - 康辰药业's shareholder Liu Jianhua reduced his stake in the company by a total of 1.0215 million shares through centralized bidding and block trading on October 17, 2025 [1] - Following this equity change, Liu Jianhua and his concerted parties' total shareholding decreased from 75.3634 million shares to 74.3419 million shares, representing a reduction in ownership from 47.29% to 46.65%, which touches the 1% threshold for equity changes [1]

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 025-10-17 | 康辰药业 | 603590 | 45.29 33 | 1494.57 | 貓影響無 | 調觀錄 | | KO | 10月17日，康辰药业大宗交易成交33万股，成交额1494.57万元，占当日总成交额的4.99%，成交价 45.29元，较市场收盘价49.22元折价7.98%。 ...

Core Insights - The biopharmaceutical sector experienced a slight increase of 0.13% on October 16, with Sanofi leading the gains [1] - The Shanghai Composite Index closed at 3916.23, up 0.1%, while the Shenzhen Component Index closed at 13086.41, down 0.25% [1] Biopharmaceutical Sector Performance - Sanofi (688336) saw a significant rise of 13.02%, closing at 59.90 with a trading volume of 177,400 shares and a transaction value of 1.063 billion [1] - Other notable gainers included: - Nossland (920047) up 4.09% to 25.46 with a transaction value of 125 million [1] - Rongchang Bio (688331) up 3.28% to 99.20 with a transaction value of 684 million [1] - Conversely, several companies experienced declines, including: - Anke Bio (300009) down 2.48% to 10.23 with a transaction value of 315 million [2] - Kain Technology (688687) down 1.92% to 28.62 with a transaction value of 169 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 2.7582 million from institutional investors, while retail investors experienced a net outflow of 140 million [2] - Notable capital inflows included: - Junshi Biosciences (688180) with a net inflow of 71.7936 million from institutional investors [3] - Sanofi (688336) with a net inflow of 67.508 million from institutional investors [3] - Conversely, significant outflows were observed in: - Sanofi (688336) with a retail net outflow of 540,300 [3] - Rongchang Bio (688331) with a retail net outflow of 4.41034 million [3]